PRA Health Sciences (PRAH) Tops Q3 EPS by 29c, Revenues Beat; Raises FY20 EPS/Revenue Guidance Above Consensus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
PRA Health Sciences, Inc. Reports Third Quarter 2020 Results and Updates Full Year 2020 Guidance
November 4, 2020 4:01 PM ESTNet new business of $737.9 million; representing growth of 10.2%; Net book-to-bill of 1.28 excluding reimbursement revenueNet new business of $986.0 million; Net book-to-bill of 1.35 including reimbursement revenue$796.3 million of total revenue; representing growth of 2.0% at actual foreign exchange rates and 1.3% on a constant currency basisGAAP net income per diluted share of $1.41; GAAP net income of $91.3 million Adjusted net income per diluted share was $1.30; Adjusted net income of $84.1 millionRaising full year 2020 revenue guidance to between $3.120 billion and $3.150 billion, GAAP net income per... More
